Targeting fatty acid metabolism in cancer and endothelial cells

Critical Reviews in Oncology/Hematology

Volumn 97, Issue , 2016, Pages 15-21

  Harjes, Ulrike ^a,b   Kalucka, Joanna ^a,b   Carmeliet, Peter ^a,b  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

Author keywords

Angiogenesis; Cancer cell metabolism; CPT1A; Endothelial cell metabolism; Fatty acid metabolism

Indexed keywords

VASCULOTROPIN RECEPTOR 2; ANGIOGENESIS INHIBITOR; FATTY ACID;

CELL METABOLISM; CELL MIGRATION; CELL PROLIFERATION; ENDOTHELIUM CELL; FATTY ACID METABOLISM; FATTY ACID OXIDATION; FATTY ACID TRANSPORT; HUMAN; MALIGNANT NEOPLASTIC DISEASE; METABOLIC REGULATION; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; DRUG EFFECTS; GLYCOLYSIS; LIPID METABOLISM; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PHYSIOLOGY; PROCEDURES; TRENDS; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ENDOTHELIAL CELLS; FATTY ACIDS; GLYCOLYSIS; HUMANS; LIPID METABOLISM; MOLECULAR TARGETED THERAPY; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 84951796601     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2015.10.011     Document Type: Review

References (101)

1. Antohe F., Popov D., Radulescu L., Simionescu N., Borchers T., Spener F., et al. Heart microvessels and aortic endothelial cells express the 15kDa heart-type fatty acid-binding proteins. Eur. J. Cell Biol. 1998, 76(2):102-109.
2. Baenke F., Peck B., Miess H., Schulze A. Hooked on fat: the role of lipid synthesis in cancer metabolism and tumour development. Dis. Model Mech. 2013, 6(6):1353-1363.
3. Balaban S., Lee L.S., Schreuder M., Hoy A.J. Obesity and cancer progression: is there a role of fatty acid metabolism?. BioMed Res. Int. 2015, 2015. 274585.
4. Bensaad K., Favaro E., Lewis C.A., Peck B., Lord S., Collins J.M., et al. Fatty acid uptake and lipid storage induced by HIF-1alpha contribute to cell growth and survival after hypoxia-reoxygenation. Cell Rep. 2014, 9(1):349-365.
5. Bickel P.E., Tansey J.T., Welte M.A. PAT proteins, an ancient family of lipid droplet proteins that regulate cellular lipid stores. Biochim. Biophys. Acta 2009, 1791(6):419-440.
6. Boiteux G., Lascombe I., Roche E., Plissonnier M.-L., Clairotte A., Bittard H., et al. A-FABP, a candidate progression marker of human transitional cell carcinoma of the bladder, is differentially regulated by PPAR in urothelial cancer cells. Int. J. Cancer 2009, 124(8):1820-1828.
7. Browne C.D., Hindmarsh E.J., Smith J.W. Inhibition of endothelial cell proliferation and angiogenesis by orlistat, a fatty acid synthase inhibitor. FASEB J. 2006, 20(12):2027-2035.
8. Cai Y., Wang J., Zhang L., Wu D., Yu D., Tian X., et al. Expressions of fatty acid synthase and HER2 are correlated with poor prognosis of ovarian cancer. Med. Oncol. 2015, 32(1):391.
9. Cao A., Li H., Zhou Y., Wu M., Liu J. Long chain acyl-CoA synthetase-3 is a molecular target for peroxisome proliferator-activated receptor delta in HepG2 hepatoma cells. J. Biol. Chem. 2010, 285(22):16664-16674.
10. Carracedo A., Weiss D., Leliaert A.K., Bhasin M., de Boer V.C., Laurent G., et al. A metabolic prosurvival role for PML in breast cancer. J. Clin. Invest. 2012, 122(9):3088-3100.
11. Carracedo A., Cantley L.C., Pandolfi P.P. Cancer metabolism: fatty acid oxidation in the limelight. Nat. Rev. Cancer 2013, 13(4):227-232.
12. Coppiello G., Collantes M., Sirerol-Piquer M.S., Vandenwijngaert S., Schoors S., Swinnen M., et al. Meox2/Tcf15 heterodimers program the heart capillary endothelium for cardiac fatty acid uptake. Circulation 2015, 131(9):815-826.
13. Currie E., Schulze A., Zechner R., Walther T.C., Farese R.V. Cellular fatty acid metabolism and cancer. Cell Metab. 2013, 18(2):153-161.
14. Dagher Z., Ruderman N., Tornheim K., Ido Y. The effect of AMP-activated protein kinase and its activator AICAR on the metabolism of human umbilical vein endothelial cells. Biochem. Biophys. Res. Commun. 1999, 265(1):112-115.
15. Dagher Z., Ruderman N., Tornheim K., Ido Y. Acute regulation of fatty acid oxidation and amp-activated protein kinase in human umbilical vein endothelial cells. Circ. Res. 2001, 88(12):1276-1282.
16. De Bock K., Georgiadou M., Schoors S., Kuchnio A., Wong B.W., Cantelmo A.R., et al. Role of PFKFB3-driven glycolysis in vessel sprouting. Cell 2013, 154(3):651-663.
17. De Rosa A., Pellegatta S., Rossi M., Tunici P., Magnoni L., Speranza M.C., et al. A radial glia gene marker, fatty acid binding protein 7 (FABP7), is involved in proliferation and invasion of glioblastoma cells. PLoS One 2012, 7(12):e52113.
18. DeFilippis R.A., Chang H., Dumont N., Rabban J.T., Chen Y.Y., Fontenay G.V., et al. CD36 repression activates a multicellular stromal program shared by high mammographic density and tumor tissues. Cancer Discov. 2012, 2(9):826-839.
19. Dewhirst M.W., Kimura H., Rehmus S.W., Braun R.D., Papahadjopoulos D., Hong K., et al. Microvascular studies on the origins of perfusion-limited hypoxia. Br. J. Cancer 1996, 27(Supplement):S247-S251.
20. Dudley A.C. Tumor endothelial cells. Cold Spring Harb. Perspect. Med. 2012, 2(3):a006536.
21. Eelen G., de Zeeuw P., Simons M., Carmeliet P. Endothelial cell metabolism in normal and diseased vasculature. Circ. Res. 2015, 116(7):1231-1244.
22. Elmasri H., Karaaslan C., Teper Y., Ghelfi E., Weng M., Ince T.A., et al. Fatty acid binding protein 4 is a target of VEGF and a regulator of cell proliferation in endothelial cells. FASEB J. 2009, 23(11):3865-3873.
23. Elmasri H., Ghelfi E., Yu C.W., Traphagen S., Cernadas M., Cao H., et al. Endothelial cell-fatty acid binding protein 4 promotes angiogenesis: role of stem cell factor/c-kit pathway. Angiogenesis 2012, 15(3):457-468.
24. Fang L.Y., Wong T.Y., Chiang W.F., Chen Y.L. Fatty-acid-binding protein 5 promotes cell proliferation and invasion in oral squamous cell carcinoma. J. Oral. Pathol. Med. 2010, 39(4):342-348.
25. Flavin R., Peluso S., Nguyen P.L., Loda M. Fatty acid synthase as a potential therapeutic target in cancer. Future Oncol. 2010, 6(4):551-562.
26. Furuhashi M., Hotamisligil G.S. Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets. Nat. Rev. Drug Discov. 2008, 7(6):489-503.
27. Gaisa N.T., Reinartz A., Schneider U., Klaus C., Heidenreich A., Jakse G., et al. Levels of acyl-coenzyme a synthetase 5 in urothelial cells and corresponding neoplasias reflect cellular differentiation. Histol. Histopathol. 2013, 28(3):353-364.
28. German N.J., Haigis M.C. Sirtuins and the metabolic hurdles in cancer. Curr. Biol. 2015, 25(13):R569-R583.
29. Glatz J.F., Luiken J.J., Bonen A. Membrane fatty acid transporters as regulators of lipid metabolism: implications for metabolic disease. Physiol. Rev. 2010, 90(1):367-417.
30. Granchi C., Minutolo F. Anticancer agents that counteract tumor glycolysis. ChemMedChem 2012, 7(8):1318-1350.
31. Greenwalt D.E., Watt K.W., Hasler T., Howard R.J., Patel S. Structural, functional, and antigenic differences between bovine heart endothelial CD36 and human platelet CD36. J. Biol. Chem. 1990, 265(27):16296-16299.
32. Griffiths B., Lewis C.A., Bensaad K., Ros S., Zhang Q., Ferber E.C., et al. Sterol regulatory element binding protein-dependent regulation of lipid synthesis supports cell survival and tumor growth. Cancer Metab. 2013, 1(1):3.
33. Hagberg C.E., Falkevall A., Wang X., Larsson E., Huusko J., Nilsson I., et al. Vascular endothelial growth factor B controls endothelial fatty acid uptake. Nature 2010, 464(7290):917-921.
34. Hagberg C., Mehlem A., Falkevall A., Muhl L., Eriksson U. Endothelial fatty acid transport: role of vascular endothelial growth factor B. Physiology 2013, 28(2):125-134.
35. Hancke K., Grubeck D., Hauser N., Kreienberg R., Weiss J.M. Adipocyte fatty acid-binding protein as a novel prognostic factor in obese breast cancer patients. Breast Cancer Res. Treat. 2010, 119(2):367-377.
36. Harjes U., Bridges E., McIntyre A., Fielding B.A., Harris A.L. Fatty acid-binding protein 4, a point of convergence for angiogenic and metabolic signaling pathways in endothelial cells. J. Biol. Chem. 2014, 289(33):23168-23176.
37. Henique C., Mansouri A., Fumey G., Lenoir V., Girard J., Bouillaud F., et al. Increased mitochondrial fatty acid oxidation is sufficient to protect skeletal muscle cells from palmitate-induced apoptosis. J. Biol. Chem. 2010, 285(47):36818-36827.
38. Hernlund E., Ihrlund L.S., Khan O., Ates Y.O., Linder S., Panaretakis T., et al. Potentiation of chemotherapeutic drugs by energy metabolism inhibitors 2-deoxyglucose and etomoxir. Int. J. Cancer 2008, 123(2):476-483.
39. Holubarsch C.J., Rohrbach M., Karrasch M., Boehm E., Polonski L., Ponikowski P., et al. A double-blind randomized multicentre clinical trial to evaluate the efficacy and safety of two doses of etomoxir in comparison with placebo in patients with moderate congestive heart failure: the ERGO (etomoxir for the recovery of glucose oxidation) study. Clin. Sci. 2007, 113(4):205-212.
40. Ito T., Yagi S., Yamakuchi M. MicroRNA-34a regulation of endothelial senescence. Biochem. Biophys. Res. Commun. 2010, 398(4):735-740.
41. Jeon S.M., Chandel N.S., Hay N. AMPK regulates NADPH homeostasis to promote tumour cell survival during energy stress. Nature 2012, 485(7400):661-665.
42. Jeong C.Y., Hah Y.S., Cho B.I., Lee S.M., Joo Y.T., Jung E.J., et al. Fatty acid-binding protein 5 promotes cell proliferation and invasion in human intrahepatic cholangiocarcinoma. Oncol. Rep. 2012, 28(4):1283-1292.
43. Kantor P.F., Lucien A., Kozak R., Lopaschuk G.D. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme a thiolase. Circ. Res. 2000, 86(5):580-588.
44. Kim S., Lee Y., Koo J.S. Differential expression of lipid metabolism-related proteins in different breast cancer subtypes. PLoS One 2015, 10(3):e0119473.
45. Knapp P., Chabowski A., Harasiuk D., Gorski J. Reversed glucose and fatty acids transporter expression in human endometrial cancer. Horm. Metab. Res. 2012, 44(6):436-441.
46. Konerding M.A., Fait E., Gaumann A. 3D microvascular architecture of pre-cancerous lesions and invasive carcinomas of the colon. Br. J. Cancer 2001, 84(10):1354-1362.
47. Kridel S.J., Axelrod F., Rozenkrantz N., Smith J.W. Orlistat is a novel inhibitor of fatty acid synthase with antitumor activity. Cancer Res. 2004, 64(6):2070-2075.
48. Lee D., Wada K., Taniguchi Y., Al-Shareef H., Masuda T., Usami Y., et al. Expression of fatty acid binding protein 4 is involved in the cell growth of oral squamous cell carcinoma. Oncol. Rep. 2014, 31(3):1116-1120.
49. Levi L., Lobo G., Doud M.K., von Lintig J., Seachrist D., Tochtrop G.P., et al. Genetic ablation of the fatty acid-binding protein FABP5 suppresses HER2-induced mammary tumorigenesis. Cancer Res. 2013, 73(15):4770-4780.
50. Liang H., Ward W.F. PGC-1alpha: a key regulator of energy metabolism. Adv. Physiol. Educ. 2006, 30(4):145-151.
51. Liu R.Z., Graham K., Glubrecht D.D., Germain D.R., Mackey J.R., Godbout R. Association of FABP5 expression with poor survival in triple-negative breast cancer: implication for retinoic acid therapy. Am. J. Pathol. 2011, 178(3):997-1008.
52. Liu R.Z., Graham K., Glubrecht D.D., Lai R., Mackey J.R., Godbout R. A fatty acid-binding protein 7/RXRbeta pathway enhances survival and proliferation in triple-negative breast cancer. J. Pathol. 2012, 228(3):310-321.
53. Lunt S.Y., Muralidhar V., Hosios A.M., Israelsen W.J., Gui D.Y., Newhouse L., et al. Pyruvate kinase isoform expression alters nucleotide synthesis to impact cell proliferation. Mol. Cell 2015, 57(1):95-107.
54. Mashek D.G., Coleman R.A. Cellular fatty acid uptake: the contribution of metabolism. Curr. Opin. Lipidol. 2006, 17(3):274-278.
55. Mashek D.G., McKenzie M.A., Van Horn C.G., Coleman R.A. Rat long chain acyl-CoA synthetase 5 increases fatty acid uptake and partitioning to cellular triacylglycerol in McArdle-RH7777 cells. J. Biol. Chem. 2006, 281(2):945-950.
56. Mashima T., Seimiya H., Tsuruo T. De novo fatty-acid synthesis and related pathways as molecular targets for cancer therapy. Br. J. Cancer 2009, 100(9):1369-1372.
57. Masouye I., Hagens G., Van Kuppevelt T.H., Madsen P., Saurat J.H., Veerkamp J.H., et al. Endothelial cells of the human microvasculature express epidermal fatty acid-binding protein. Circ. Res. 1997, 81(3):297-303.
58. McCarty M.F. AMPK activation as a strategy for reversing the endothelial lipotoxicity underlying the increased vascular risk associated with insulin resistance syndrome. Med. Hypotheses 2005, 64(6):1211-1215.
59. McGuirk S., Gravel S.P., Deblois G., Papadopoli D.J., Faubert B., Wegner A., et al. PGC-1alpha supports glutamine metabolism in breast cancer. Cancer Metab. 2013, 1(1):22.
60. McIntyre A., Harris A.L. Metabolic and hypoxic adaptation to anti-angiogenic therapy: a target for induced essentiality. EMBO Mol. Med. 2015, 7(4):368-379.
61. Metallo C.M., Gameiro P.A., Bell E.L., Mattaini K.R., Yang J., Hiller K., et al. Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia. Nature 2012, 481(7381):380-384.
62. Nash D.T., Nash S.D. Ranolazine for chronic stable angina. Lancet 2008, 372(9646):1335-1341.
63. Neubauer S. The failing heart-an engine out of fuel. New Engl. J. Med. 2007, 356(11):1140-1151.
64. Nieman K.M., Kenny H.A., Penicka C.V., Ladanyi A., Buell-Gutbrod R., Zillhardt M.R., et al. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat. Med. 2011, 17(11):1498-1503.
65. Nomura D.K., Long J.Z., Niessen S., Hoover H.S., Ng S.-W., Cravatt B.F. Monoacylglycerol lipase regulates a fatty acid network that promotes cancer pathogenesis. Cell 2010, 140(1):49-61.
66. Nomura D.K., Lombardi D.P., Chang J.W., Niessen S., Ward A.M., Long J.Z., et al. Monoacylglycerol lipase exerts dual control over endocannabinoid and fatty acid pathways to support prostate cancer. Chem. Biol. 2011, 18(7):846-856.
67. Patella F., Schug Z.T., Persi E., Neilson L.J., Erami Z., Avanzato D., et al. Proteomics-based metabolic modeling reveals that fatty acid oxidation (FAO) controls endothelial cell (EC) permeability. Mol. Cell. Proteomics 2015, 14(3):621-634.
68. Pei Z., Sun P., Huang P., Lal B., Laterra J., Watkins P.A. Acyl-CoA synthetase VL3 knockdown inhibits human glioma cell proliferation and tumorigenicity. Cancer Res. 2009, 69(24):9175-9182.
69. Pei Z., Fraisl P., Shi X., Gabrielson E., Forss-Petter S., Berger J., et al. Very long-chain acyl-CoA synthetase 3: overexpression and growth dependence in lung cancer. PLoS One 2013, 8(7):e69392.
70. Pike L.S., Smift A.L., Croteau N.J., Ferrick D.A., Wu M. Inhibition of fatty acid oxidation by etomoxir impairs NADPH production and increases reactive oxygen species resulting in ATP depletion and cell death in human glioblastoma cells. Biochim. Biophys. Acta 2011, 1807(6):726-734.
71. Potente M., Gerhardt H., Carmeliet P. Basic and therapeutic aspects of angiogenesis. Cell 2011, 146(6):873-887.
72. Powell C.A., Nasser M.W., Zhao H., Wochna J.C., Zhang X., Shapiro C., et al. Fatty acid binding protein 5 promotes metastatic potential of triple negative breast cancer cells through enhancing epidermal growth factor receptor stability. Oncotarget 2015, 6(8):6373-6385.
73. Rysman E., Brusselmans K., Scheys K., Timmermans L., Derua R., Munck S., et al. De novo lipogenesis protects cancer cells from free radicals and chemotherapeutics by promoting membrane lipid saturation. Cancer Res. 2010, 70(20):8117-8126.
74. Saha A.K., Schwarsin A.J., Roduit R., Masse F., Kaushik V., Tornheim K., et al. Activation of malonyl-CoA decarboxylase in rat skeletal muscle by contraction and the AMP-activated protein kinase activator 5-aminoimidazole-4-carboxamide-1-beta--ribofuranoside. J. Biol. Chem. 2000, 275(32):24279-24283.
75. Samudio I., Harmancey R., Fiegl M., Kantarjian H., Konopleva M., Korchin B., et al. Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis induction. J. Clin. Invest. 2010, 120(1):142-156.
76. Sargsyan E., Bergsten P. Lipotoxicity is glucose-dependent in INS-1E cells but not in human islets and MIN6 cells. Lipids Health Dis. 2011, 10:115.
77. Schafer Z.T., Grassian A.R., Song L., Jiang Z., Gerhart-Hines Z., Irie H.Y., et al. Antioxidant and oncogene rescue of metabolic defects caused by loss of matrix attachment. Nature 2009, 461(7260):109-113.
78. Schlaepfer I.R., Rider L., Rodrigues L.U., Gijon M.A., Pac C.T., Romero L., et al. Lipid catabolism via CTP1 as a therapeutic target for prostate cancer. Mol. Cancer Ther. 2014, 10:2361-2371.
79. Schoors S., De Bock K., Cantelmo A.R., Georgiadou M., Ghesquiere B., Cauwenberghs S., et al. Partial and transient reduction of glycolysis by PFKFB3 blockade reduces pathological angiogenesis. Cell Metab. 2014, 19(1):37-48.
80. Schoors S., Cantelmo A.R., Georgiadou M., Stapor P., Wang X., Quaegebeur A., et al. Incomplete and transitory decrease of glycolysis: a new paradigm for anti-angiogenic therapy?. Cell Cycle 2014, 13(1):16-22.
81. Schoors S., Bruning U., Missiaen R., Queiroz K.C., Borgers G., Elia I., et al. Fatty acid carbon is essential for dNTP synthesis in endothelial cells. Nature 2015, 520(7546):192-197.
82. Schug Z.T., Peck B., Jones D.T., Zhang Q., Grosskurth S., Alam I.S., et al. Acetyl-CoA synthetase 2 promotes acetate utilization and maintains cancer cell growth under metabolic stress. Cancer Cell 2015, 27(1):57-71.
83. Seguin F., Carvalho M.A., Bastos D.C., Agostini M., Zecchin K.G., Alvarez-Flores M.P., et al. The fatty acid synthase inhibitor orlistat reduces experimental metastases and angiogenesis in B16-F10 melanomas. Br. J. Cancer 2012, 107(6):977-987.
84. Semenkovich C.F. Fatty acid metabolism and vascular disease. Trends Cardiovasc. Med. 2004, 14(2):72-76.
85. Smolkova K., Jezek P. The role of mitochondrial NADPH-dependent isocitrate dehydrogenase in cancer cells. Int. J. Cell Biol. 2012, 2012. 273947.
86. Sun Y., He W., Luo M., Zhou Y., Chang G., Ren W., et al. SREBP1 regulates tumorigenesis and prognosis of pancreatic cancer through targeting lipid metabolism. Tumour Biol. 2015, 6. 4133-416.
87. Tirado-Velez J.M., Joumady I., Saez-Benito A., Cozar-Castellano I., Perdomo G. Inhibition of fatty acid metabolism reduces human myeloma cells proliferation. PLoS One 2012, 7(9):e46484.
88. Tomasetti M., Santarelli L., Neuzil J., Dong L. MicroRNA regulation of cancer metabolism: role in tumour suppression. Mitochondrion 2014, 19(Pt. A):29-38.
89. Uehara H., Takahashi T., Oha M., Ogawa H., Izumi K. Exogenous fatty acid binding protein 4 promotes human prostate cancer cell progression. Int. J. Cancer 2014, 135(11):2558-2568.
90. Vander Heiden M.G. Exploiting tumor metabolism: challenges for clinical translation. J. Clin. Invest. 2013, 123(9):3648-3651.
91. Vavvas D., Apazidis A., Saha A.K., Gamble J., Patel A., Kemp B.E., et al. Contraction-induced changes in acetyl-CoA carboxylase and 5'-AMP-activated kinase in skeletal muscle. J. Biol. Chem. 1997, 272(20):13255-13261.
92. Watanabe K., Wakabayashi H., Veerkamp J.H., Ono T., Suzuki T. Immunohistochemical distribution of heart-type fatty acid-binding protein immunoreactivity in normal human tissues and in acute myocardial infarct. J. Pathol. 1993, 170(1):59-65.
93. Wei X., Schneider J.G., Shenouda S.M., Lee A., Towler D.A., Chakravarthy M.V., et al. De novo lipogenesis maintains vascular homeostasis through endothelial nitric-oxide synthase (eNOS) palmitoylation. J. Biol. Chem. 2011, 286(4):2933-2945.
94. Winder W.W., Hardie D.G. Inactivation of acetyl-CoA carboxylase and activation of AMP-activated protein kinase in muscle during exercise. Am. J. Physiol. 1996, 270(2 Pt.1):E299-E304.
95. Xie S., Zhou F., Wang J., Cao H., Chen Y., Liu X., et al. Functional polymorphisms of ATP citrate lyase gene predicts clinical outcome of patients with advanced colorectal cancer. World J. Surg. Oncol. 2015, 13(1):42.
96. Xu Y., An X., Guo X., Habtetsion T.G., Wang Y., Xu X., et al. Endothelial PFKFB3 plays a critical role in angiogenesis. Arterioscler. Thromb. Vasc. Biol. 2014, 34(6):1231-1239.
97. Xue Y., Wei Z., Ding H., Wang Q., Zhou Z., Zheng S., et al. MicroRNA-19b/221/222 induces endothelial cell dysfunction via suppression of PGC-1alpha in the progression of atherosclerosis. Atherosclerosis 2015, 241(2):671-681.
98. Ye L., Zhang B., Seviour E.G., Tao K.X., Liu X.H., Ling Y., et al. Monoacylglycerol lipase (MAGL) knockdown inhibits tumor cells growth in colorectal cancer. Cancer Lett. 2011, 307(1):6-17.
99. Zaugg K., Yao Y., Reilly P.T., Kannan K., Kiarash R., Mason J., et al. Carnitine palmitoyltransferase 1C promotes cell survival and tumor growth under conditions of metabolic stress. Genes Dev. 2011, 25(10):1041-1051.
100. Zaytseva Y.Y., Elliott V.A., Rychahou P., Mustain W.C., Kim J.T., Valentino J., et al. Cancer cell-associated fatty acid synthase activates endothelial cells and promotes angiogenesis in colorectal cancer. Carcinogenesis 2014, 35(6):1341-1351.
101. Zong H., Zhang Y., You Y., Cai T., Wang Y. Decreased Warburg effect induced by ATP citrate lyase suppression inhibits tumor growth in pancreatic cancer. Med. Oncol. 2015, 32(3):85.